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ABSTRACT
Background: There is a need for patient-reported out-
come measures that capture the impact that motor
impairments have on health-related quality of life in
individuals with Huntington’s disease.
Objectives: The objectives of this study were to estab-
lish the reliability and validity of new physical function-
ing patient-reported outcome measures in Huntington’s
disease.
Methods: A total of 510 individuals with Huntington’s
disease completed 2 Quality of Life in Neurological
Disorders (Lower Extremity Function and Upper
Extremity Function) and 3 Huntington’s Disease Health-
Related Quality of Life (Chorea, Speech Difficulties, and
Swallowing Difficulties) measures. Clinician-rated and
generic self-report measures were also administered.
Results: Reliabilities for the new patient reported
physical functioning measures were excellent (all Cron-
bach’s a> .92). Convergent, discriminant validity and
known group validity was supported.
Conclusions: The results provide psychometric sup-
port for new patient-reported physical functioning mea-
sures and the fact that these measures can be used
as clinically meaningful endpoints in Huntington’s dis-
ease research and clinical practice. VC 2017 Internation-
al Parkinson and Movement Disorder Society
Key Words: Neuro-QoL; HDQLIFE; Huntington’s dis-
ease; physical functioning; chorea; motor symptoms;
health-related quality of life; patient-reported outcome
(PRO)
Huntington’s disease (HD) is a progressive neurode-
generative disorder that causes profound cognitive,
behavioral, and motor declines. The motor
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phenomenology in HD is multifaceted and affects all
body segments and limbs, with profound impacts on
daily living and social participation. The most charac-
teristic and best studied motor symptom in HD is cho-
rea.1-4 Chorea is associated with falls, gait
disturbance, and balance difficulties.5-10 By mid- to
late-stage HD, even if chorea is controlled, a host of
less-treatable motor problems steadily worsen (dysto-
nia, bradykinesia, rigidity, and ataxia). Motor symp-
toms also affect oropharyngeal function resulting in
worsening dysarthria11-13 and dysphagia.14
Patient-reported outcome (PRO) measures about
motor symptoms and associated activity limitations
are rarely used in HD trials, even though such out-
comes are increasingly recognized as important mea-
sures of efficacy for new treatments.15 In a devastating
disease such as HD, where intensive treatment efforts
are directed at the development of treatments designed
to improve physical activity engagement,16-21 there is
a particular need for meaningful and sensitive PRO
measures that capture these aspects of health-related
quality of life (HRQOL).
The Huntington Disease Health-Related Quality of
Life (HDQLIFE) measurement system22-25 was
designed to provide reliable and valid assessments of
HRQOL among individuals with HD. This system
includes several HD-specific measures of HRQOL as
well as generic HRQOL measures from the Quality of
Life in Neurological Disorders (Neuro-QoL) sys-
tem.26,27 The goal of this paper is to provide reliability
and validity data for the HDQLIFE PROs that evalu-
ate physical function.
Methods
Participants
Individuals with either prodromal (gene-positive sta-
tus for the HD CAG expansion and no clinical diag-
nosis) or manifest HD were invited to participate in
this study. Participants were18 years of age, able to
read and understand English, and had the ability to
provide informed consent. Participants were recruited
through specialized HD treatment centers, the HD
Roster, existing data capture systems,28 and the
Predict-HD research study.29
Measures
We examined Neuro-QoL Lower Extremity Func-
tion and Neuro-QoL Upper Extremity Function19,29
computer adaptive tests and fixed 8-item short-forms.
We also examined simulated computer adaptive tests
and 6-item short-form scores for HDQLIFE Chorea,30
HDQLIFE Speech Difficulties,31 and HDQLIFE Swal-
lowing Difficulties.31 Resulting scores are on a t-metric
(mean [M]5 50, standard deviation [SD]5 10).
Composite Scores
Upper and lower extremity composite scores were creat-
ed by the a priori selection of self-rated and clinician-rated
items. The upper extremity self-rated composite was com-
posed of the EuroQoL 5 Dimensions Questionnaire32 self-
care item, 1 Veterans Rand 12-itemHealth Status Invento-
ry33 item (“Does your health now limit you in moderate
activities, such as moving a table, pushing a vacuum clean-
er, bowling, or playing golf? If so, how much?”), 2 World
HealthOrganizationDisability Assessment Schedule 2.034
items (“In the last 30 days, how much difficulty did you
have in: washing your whole body?” and “In the last 30
days, how much difficulty did you have in: getting
dressed?”), and items from a self-report version of the
UHDRS35 Total Functional Capacity (TFC; “Are you able
to work?” Are you able to manage your own finances?”
“Are you able to complete household chores without
help?” “Are you able to accomplish daily living tasks,
such as bathing, dressing, and meal preparation without
help?” “What type of care do you receive?”). Self-
reported TFC internal consistency (Cronbach’s a5 0.86)
and convergent validity with the clinician-rated version
(intraclass correlation coefficient [ICC]5 0.89; 95% con-
fidence interval .87-.91) were supported. The lower
extremity self-rated composite was composed of the Euro-
QoL 5 Dimensions Questionnaire32 mobility item, 1
Rand33 item (“Does your health now limit you in climbing
several flights of stairs? If so, how much?”), 2 World
HealthOrganizationDisability Assessment Schedule 2.034
items (“In the last 30 days, how much difficulty did you
have in: standing for long periods such as 30 minutes?”
and “In the last 30 days, howmuch difficulty did you have
in: walking a long distance, such as a kilometer [or equiv-
alent]?”), and the self-reported TFC items. The upper
extremity clinician-rated composite was composed of the
UHDRS35 Independence Scale, TFC score, and Motor
Assessment upper extremity items (finger tapping, prona-
tion, and hand supination; Luria; arm rigidity; upper
extremity dystonia; upper extremity chorea). The lower
extremity clinician-rated composite was composed of the
Independence Scale, TFC score, and Motor Assessment
lower extremity items (gait, tandemwalking, retropulsion,
lower extremity dystonia, lower extremity chorea). All
composite scores were coded so that higher scores indicat-
ed worse function; scores were transformed to z scores,
averaged, and transformed to t scores (M5 50, SD510).
Clinician-rated TFC was used to classify manifest
HD participants as either early stage (sum scores of 7-
13) or late stage (sum scores of 0-6).36
Analyses
Internal Consistency Reliability, Convergent
and Discriminant Validity
A multitrait, multimethod correlation matrix where
Pearson correlation coefficients are organized such that
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each method (PRO and composite measures) is arranged
corresponding to different concepts (clinician ratings or
self-reported) was used to examine internal consistency
reliability (Cronbach’s alphas) and determine associa-
tions among PROs, self-rated, and clinician-rated com-
posites. Coefficients on the diagonal provide estimated
reliabilities. Coefficients between similar methods and
concepts (eg, PRO vs PRO composite) should yield the
strongest relationships (correlations 0.6 support con-
vergent validity), and coefficients between different
methods and concepts (eg, PRO vs clinician composite)
should yield the weakest relationships (0.3 to 0.6 corre-
lations support discriminant validity).37
Known-Groups Analyses
Multivariate analyses were conducted to identify group
differences (prodromal, early HD, late HD). Prodromal
participants should report better functioning than both
manifest HD groups; early-HD participants should report
better functioning than late-HD participants.
Effect Sizes
Cohen’s d were calculated to evaluate the relative
influence that symptom severity (determined by a
median split using the corresponding clinician-rated
scores/item[s] from the UHDRS Motor Assessment)
had on self-reported physical functioning. Neuro-QOL
scores were compared with the UHDRS Total Motor
score, HDQLIFE Chorea was compared with the
clinician-rated UHDRS Motor Assessment chorea
items, HDQLIFE Speech Difficulties was compared
with the clinician-rated UHDRS Motor Assessment
speech item, and HDQLIFE Swallowing Difficulties
was compared with the clinician-rated UHDRS Motor
Assessment swallowing item. Effect sizes for the
Neuro-QoL PROs were examined relative to the
Neuro-QoL normative sample (n51046 for Lower
Extremity; n51095 for Upper Extremity; M550,
SD5 10); effect sizes for each HDQLIFE PRO was
examined relative to this sample. The largest effect
sizes should be seen among those with greater
clinician-rated severity.
Classification Accuracy (Sensitivity/Specificity)
Logistic regression models were conducted to deter-
mine the accuracy with which the PROs could dis-
criminate between different HD groups. Likelihood
ratios for clinical decision making should be 2.38
Receiver operating characteristic analysis was used to
compare diagnostic performance of the PROs (mini-
mal acceptable area under the curve specified
as .70.39
Results
A total of 510 individuals with prodromal
(n5198), early- (n5 195), or late-stage HD (n5117)
participated in this study. Participants ranged from 18
to 81 years of age (M549.10, SD513.23), 59.2% of
participants were women, and the majority of partici-
pants were white (96.1%). Education ranged from 4
to 26 years (M5 15.06, SD5 2.89). Descriptive data
for the PROs are provided in Table 1. An examination
of floor effects by group (prodromal, early-, and late-
stage HD) confirmed that floor effects were most prev-
alent in the prodromal group (of those with floor
effects, 65% were prodromal participants).
Internal Consistency Reliability, Convergent
and Discriminant Validity
Reliability coefficients for the Neuro-QoL (both5 .97)
and HDQLIFE measures were excellent (.98 for Chorea
and Speech, .97 for Swallowing; Table 1). Validity coeffi-
cients were higher between the Neuro-QoL/HDQLIFE
measures and the composite self-report measures than
they were with the clinician-rated composites, supporting
convergent and discriminant validity, respectively.
Known-Groups Analyses
Analyses indicated significant group differences
among all 3 groups; findings were in the predicted
direction (Table 2).
Effect Sizes
As expected, effect sizes were larger for the groups
with more clinician-rated severity (Table 2).
Classification Accuracy
(Sensitivity/Specificity)
Classification accuracy was generally moderate to high
for all PROs when differentiating between prodromal-
HD and either manifest HD group (Table 2).
Discussion
The results support the reliability and validity of the
Neuro-QoL and HDQLIFE physical functioning PROs
in individuals with prodromal and manifest HD. Spe-
cifically, the results provided strong support for the
internal consistency reliability of the PROs, and
although there was some evidence of floor effects
(which reflected the fact that the majority of the pro-
dromal group was not exhibiting motor problems),
these PROs were free of ceiling effects. Convergent
and discriminant validity of the PROs were also sup-
ported. Specifically, convergent validity was supported
by strong associations between the physical function-
ing PROs and other measures of self-reported physical
functioning, and discriminant validity was supported
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by slightly smaller associations between the PROs and
the clinician-rated composites.
As expected, we also found that individuals with
prodromal HD had less physical dysfunction than
either manifest HD group and that individuals with
late HD had more severe motor functional impair-
ments than early HD. Furthermore, effect sizes for the
PROs were higher for participants with lower
clinician-rated functioning than those with better func-
tioning. Together, these findings support the construct
validity of these new measures in HD.
Finally, moderate to high sensitivity and specificity
were found for almost all the new PROs. In particular,
scores on all PROs suggested that they could be used
to discriminate between individuals with prodromal
and early HD, and between prodromal and late HD
(except HDQLIFE Swallowing Difficulties), suggesting
that these measures may be especially sensitive to
tracking disease progression over time.
Although this study provides important psychometric
support for these new PROs, there are limitations to
this study. First, participants were recruited through
other research studies and through established HD clin-
ics; this convenience sample may not represent the HD
population at large. Furthermore, multitrait, multime-
thod analyses relied on composite scores that were gen-
erated using individual items from existing scales and
self-report versions of clinician-administered measures.
This departure from their intended use and/or standard-
ized administration may either over- or underestimate
the participants’ “true” abilities, which could potential-
ly weaken the interpretation of this validity data. Final-
ly, symptom progression in HD includes cognitive
impairments40-45 and anosognosia (lack of self-aware-
ness)46 that may preclude the ability to examine
HRQOL using PROs. Regardless, such self-report mea-
sures should be used in conjunction with other informa-
tion (eg, performance-based and clinician-rated
assessments) when making clinical decisions, especially
among individuals who are later in the disease process.
The Neuro-QoL and HDQLIFE PROs provide brief,
reliable, and valid assessments of physical functioning.
TABLE 2. Known-groups validity, effect sizes, and classification accuracy of the new patient-reported outcome computer
adaptive tests
Known-groups validity
Prodromal HD
(n5 197)
Early HD
(n5188)
Late HD
(n5 106)
F Partial h2
Clinician-Rated
Severity on
UHDRS Motor
Exam item(s)
Mean SD Mean SD Mean SD Low High
Lower Extremity Function/Mobilitya,b,c 56.07 7.33 46.92 8.91 0.401 8.59 163.021 0.401 20.71 0.52
Upper Extremity Function - Fine Motor ADLa,b,c 52.49 6.60 43.24 8.85 0.467 7.98 214.214 0.467 21.15 0.12
Known-group validity
Prodromal HD
(n5 194)
Early HD
(n5 191)
Late HD
(n5106)
F Partial h2
Clinician-Rated
Severity on
UHDRS Motor
Exam item(s)
Mean SD Mean SD Mean Low Low High
HDQLIFE Choreaa,b,c 43.43 3.80 51.64 7.83 0.391 8.27 156.978 0.391 1.40 20.09
HDQLIFE Speech Difficultiesa,b,c 42.87 6.16 50.29 7.56 0.309 7.62 109.143 0.309 2.20 20.19
HDQLIFE Swallowing Difficultiesa,b,c 44.17 5.70 51.03 8.19 0.296 7.97 102.354 0.296 0.44 20.06
Classification accuracy
Prodromal vs Early Prodromal vs Late Early vs Late
Sensitivity,
specificity
Area under
the curve
Likelihood
ratio
Sensitivity,
specificity
Area under
the curve
Likelihood
ratio
Sensitivity,
specificity
Area under
the curve
Likelihood
ratio
Lower Extremity Function/Mobility 70.2, 72.1 0.78 2.36 86.8, 92.9 0.95 6.58 55.7, 82.4 0.80 1.26
Upper Extremity Function - Fine Motor ADL 72.3, 70.6 0.78 2.61 77.6, 88.8 0.93 3.46 52.3, 85.1 0.75 1.10
HDQLIFE Chorea 82.2, 79.6 0.86 4.62 77.2, 91.6 0.92 3.39 22.8, 91.4 0.67 0.30
HDQLIFE Speech Difficulties 70.7, 69.9 0.78 2.41 70.0, 87.0 0.87 2.33 24.5, 92.7 0.66 0.32
HDQLIFE Swallowing Difficulties 68.1, 71.6 0.74 2.13 60.7, 84.5 0.84 1.54 17.9, 92.7 0.62 0.22
All P<.0001. There were significant differences among all 3 groups for all Neuro-QoL and HDQLIFE measures. Neuro-QoL, Quality of Life in Neurological Dis-
orders Measurement System; HDQLIFE, Huntington Disease Health-Related Quality of Life Measurement System; HD, Huntington’s disease; CAT, computer
adaptive test; ADL, activities of daily living.
aSignificant differences between prodromal and early HD.
bSignificant differences between prodromal and late HD.
cSignificant differences between early HD and late HD.
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Furthermore, these PROs are able to differentiate
between individuals with prodromal versus early- or
late-stage HD. As such, these measures fill a significant
gap in HD clinical interventions where sensitive PROs
are needed to detect improvements in motor impair-
ment and physical activity engagement.
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